Analyst rating coverage is not available for TAK yet.
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 19, 2026 vs $21.28 current
Highest Target—
Average Target—
Lowest Target—
TAK analyst recommendation trends
86420
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
0
0
0
0
0
0
Neutral
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
0
0
0
0
0
0
As of Nov 19, 2026, 0 of 0 active firms rate TAK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TAK EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 4 analysts
Next period, 4 analysts expect Takeda Pharmaceutical Co Ltd ADR to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $62.14, growing to $197.77 the year after.
REVENUE · NEXT QUARTER
$1.1T
Range $1.0T – $1.2T · 4 analysts · +4% YoY
Revenue is expected to reach $1.1T (range $1.0T – $1.2T), +4.2% year-over-year. Full-year consensus is $4.7T, rising to $4.8T next year.
Top analysts covering Takeda Pharmaceutical Co Ltd ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TAK.
#1
MN
Michael Nedelcovych
TD Cowen
Buy
$21.00-1.3% to target
Coverage
—
+ Follow
TAK stock forecast FAQ
Who is the most accurate analyst covering TAK?+
Among analysts who currently cover TAK, Michael Nedelcovych of TD Cowen has the strongest overall Quantellect track record. Their current call is Buy with a $21.00 target.
What is Takeda Pharmaceutical Co Ltd ADR's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 4 analysts. Full-year EPS is projected at $62.14, rising to $197.77 the following year.
How much revenue is Takeda Pharmaceutical Co Ltd ADR expected to report next quarter?+
Consensus revenue is $1.1T (range $1.0T – $1.2T). Full-year revenue is projected at $4.7T, growing to $4.8T next year.
Have analysts been upgrading or downgrading TAK lately?+
As of Nov 19, 2026, 0 of 0 active firms rate TAK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TAK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.